October 7, 2015 6:51pm

 

I am still looking for the rebound influences on the sector, other than “algorithmic programs”. Digesting repetitive dips and readjustments do not adequately support pricing sustainability as the sector has yet to find a bottom!

Subscription required: http://www.regmedinvestors.com/user/register

 

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

 

 

U.S. stocks closed higher Wednesday, helped by a recovery in health care stocks. Health care was the greatest advancer in the S&P 500 on the day, helping the index come within 5 points of the psychologically key 2,000 level.

The NASDAQ closed UP +42.79 or +0.90% to 4,791.15 and the DOW closed UP +122.10 or +0.73% to 16,912.29.

 

 

Henry’omics”:

There was a bit of a bias to buy at the open, the stem, cell, gene therapy and regenerative medicine (SCGT&RM). As the session advanced, stock prices were just bouncing around in the morning session.

  • The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 18.5, down from last night’s below 20.

The hourly afternoon session skipped from 26 to 30 to end with 26 advancers out of 43 companies covered.

  • For months, the SCGT&RM sector has resisted finding a bottom weighing in to depreciation and profiteering, which has divided investors forced to choose between holding their current positions on a hope-enhanced P2 safety and efficacy trials or exiting for early tax loss selling.

The NASDAQ composite outperformed as the iShares Nasdaq Biotechnology ETF (IBB) recovered recent losses with gains of 1.95%.

  • I keep talking to investors and funds hoping they will get me the information they gathered but, I seem to have more actionable information than they; so I end up providing the G-2 … so they could make a number of “decisions”.

Talk about being king of the pile <of what though> – the first to aggregate the info (?).  The awkward dynamic wasn't a surprise!

  • The NASDAQ Biotechnology index (NBI) closed DOWN – 123.79  or -3.77% after yesterday’s <Monday> -22.39 or -0.68%;
  • The iShares Nasdaq Biotechnology ETF (IBB) closed UP on Wednesday +5.88 or +1.95% following Tuesday decline of -11.29 or -3.60% after Monday’s -2.33 or -0.74%;
  • The Russell 2000 (IWM) closed UP +1.99 or +1.77% after Tuesday’s decline of -0.78 or -0.69% after Monday’s advance of +2.66 or +2.40%;
  • The SPDR SD&P Biotech ETF (XBI) closed UP +1.27 or +2.01% after Tuesday’s decline of -2.81 or -4.21% after Mondays’ advance of +0.56 or +0.79%;
  • The NYSE ARCA Biotech Index (BTK) closed DOWN on Wednesday -17.97 or -0.45% after Tuesday’s plunge of -17.97 or -0.45% - same numbers (?).      

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

  • SCGT & RM equities opened negative with an A/DL of 9/27 and 6 flats resetting the scoreboard for a positive mid-day A/DL of 26/15 and 2 flats.
  • The 2 pm SCGT & RM equities continued to swing positive with an A/DL of 30/11 and 2 flats. The closing bell stayed positive with an A/DL of 14/26 and 3 flats

The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, held just below 20.

 

 

Dosing the sector – 43 Patients:

  • Open: NEGATIVE with 27 decliners, 9 advancers and 6 flats;
  • Mid-day (12:30 pm) POSITIVE with15 decliners, 26 advancers and 2 flats;
  • Closing bell: POSITIVE with 14 decliners, 26 advancers and 3 flats

 

 

Wednesday’s trading indications: 8 hit/ 0 miss:

  • Applied Genetic Technologies (AGTC) closed UP – hit;
  • blue bird bio (BLUE) closed DOWN – hit;
  • Capricor (CAPR) closed DOWN – hit;
  • Fate Therapeutics (FATE) closed UP – hit;
  • Juno Therapeutics (JUNO) closed UP – hit;
  • Kite Pharma (KITE) closed UP – hit;
  • Spark Therapeutics (ONCE) closed DOWN – hit;
  • Verastem (VSTM) closed UP – hit;

 

 

Who is UP – highest 5:

  • Intrexon (XON) closed up +$2.64 to $33.71;
  • Kite Pharma (KITE) +$1.60 to $64.57;
  • Juno Therapeutics (JUNO)+$1.42 to $48.74;
  • Regenxbio (RGNX) +$1.20 to $23.40;
  • Bellicum (BLCM) closed uo +$0.96 to $15.45;

 

 

Who is down - the lowest 5:

  • Spark Therapeutics (ONCE) closed down -$5.59 to $44.81;
  • uniQure (QURE) -$0.66 to $20.01;
  • bluebird bio (BLUE) -$0.50 to $94.30;
  • Vericel (VCEL) closed down -$0.27 to $2.42;
  • ReNeuron (RENE.L) closed down -0.25 to $3.875

 

 

Who is flat?

  • Pluristem (PSTI) at $1.78;
  • Organovo (ONVO) at $2.81;
  • VistaGen (VSTA) at $9.50

 

 

All investments are subject to risks. Investors should consider investment objectives. The information included above as well as individual companies and/or securities mentioned should only construed as an indication from any RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.